IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance

By D. Munn, A. Mellor. Trends in immunology, 2016

922 citations recorded by the source corpus.

Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory roles associated tryptophan metabolism. These include counter-regulation (controlling inflammation) and acquired tolerance in T cells. Recent findings reveal that IDO can be triggered by innate responses during tumorigenesis, and also by attempted T cell activation, either spontaneous or due to immunotherapy. Here we review the current understanding of mechanisms by which IDO participates in the control of inflammation and in peripheral tolerance. Focusing on the tumor microenvironment, we examine the role of IDO in response to apoptotic cells and the impact of IDO on Treg cell function. We discuss how the counter-regulatory and tolerogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the current clinical progress in this area.

Subfields: Biological Psychiatry, Immunology, Neurology

View Paper: https://www.semanticscholar.org/paper/cc93ea7a21c0f991cfb6de896502b810fbba9f5d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Labani-Motlagh
2. Mehrnoush Ashja-Mahdavi
3. A. Loskog

Citations in the corpus

• The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses (2020, background): “Moreover, IDO influences PD-1 overexpression by Tregs and these cells in turn stimulate expression of PD-L1 and PD-L2 on DCs (235).”
• Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020, background): “Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018; Prasad et al., 2004; Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”